Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index Ana Ortega-FrancoClare HodgsonRaffaele Califano Original Research Article 04 July 2022 Pages: 453 - 465
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma Bruno Almeida CostaTarek H. MouhieddineJoshua Richter Review Article 30 June 2022 Pages: 383 - 405
Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer Elaine S. TanWenyi FanHao Xie Original Research Article 29 June 2022 Pages: 483 - 492
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study Marco MaruzzoFrancesco PierantoniVittorina Zagonel Original Research Article Open access 25 June 2022 Pages: 467 - 474
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma Suzette GirgisShun Xin Wang LinYusri Elsayed Original Research Article Open access 24 June 2022 Pages: 433 - 439
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study Abdulazeez SalawuAaron R. HansenAlbiruni R. Abdul Razak Original Research Article 30 May 2022 Pages: 271 - 281
Antibody–Drug Conjugates in Uro-Oncology Dawid SigorskiPaweł RóżanowskiKatarzyna Wiktorska Review Article 14 May 2022 Pages: 203 - 221
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy Takuro MizukamiMasaki TakahashiTakako Eguchi Nakajima Original Research Article 07 May 2022 Pages: 343 - 353
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer Lesley J. Scott Correction Open access 05 May 2022 Pages: 381 - 381
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC James E. Frampton Adis Drug Evaluation 17 June 2022 Pages: 369 - 376
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors Joan R. E. ChooYi-Hua JanSoo Chin Lee Original Research Article Open access 14 June 2022 Pages: 355 - 368
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor Laura C. KennedyJun LuVijayakrishna K. Gadi Original Research Article 13 June 2022 Pages: 329 - 341
Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer Andrew J. KlinkAbhishek KavatiRuth Antoine Original Research Article Open access 18 June 2022 Pages: 321 - 328
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study Tanya TrippettHelen ToledanoBirgit Geoerger Original Research Article Open access 17 June 2022 Pages: 283 - 293
When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents Daniel V. AraujoBruno UchoaMarc Oliva Review Article 10 June 2022 Pages: 253 - 270
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era Hiroki IshiharaYuki NemotoToshio Takagi Original Research Article 23 April 2022 Pages: 307 - 319
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan Yen-Hsiang HuangKuo-Hsuan HsuGee-Chen Chang Original Research Article Open access 23 April 2022 Pages: 295 - 306
Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review Thomas D. McLeanSerena DuchiClaudia Di Bella Review Article Open access 21 April 2022 Pages: 223 - 252
Correction to: MYL-1402O: A Bevacizumab Biosimilar Arnold Lee Correction Open access 18 April 2022 Pages: 379 - 379
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies Toshio ShimizuYasutoshi KubokiKyu-pyo Kim Correction Open access 12 April 2022 Pages: 377 - 377
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors Amita PatnaikShirish GadgeelPeter J. O’Dwyer Original Research Article 28 March 2022 Pages: 125 - 138
Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) Dat LeCraig VargoMichael Berger Original Research Article 24 March 2022 Pages: 167 - 175
Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer Fawzi Abu RousRadhika GuttaShirish Gadgeel Short Communication 21 March 2022 Pages: 187 - 192
Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer Ping FanV. Craig Jordan Review Article 15 March 2022 Pages: 111 - 124
The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours Tiffany FooDavid GoldsteinAmitesh C. Roy Review Article Open access 15 March 2022 Pages: 95 - 110
Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers Hiroyuki TakedaKiyomi ImotoYu Sunakawa Original Research Article 02 April 2022 Pages: 177 - 185
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors Amita PatnaikShirish GadgeelPeter J. O’Dwyer Correction 05 April 2022 Pages: 139 - 139
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis Suzy Van SandenMolly MurtonAlastair Greystoke Original Research Article Open access 28 February 2022 Pages: 153 - 166
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors Matilda Xinwei LeeAndrea L. A. WongSoo Chin Lee Original Research Article Open access 23 February 2022 Pages: 141 - 151
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma Anthony Markham Adis Drug Evaluation 17 February 2022 Pages: 193 - 201
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System Monia SisiMichele FusaroliFrancesco Gelsomino Original Research Article Open access 13 January 2022 Pages: 43 - 51
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China Hai-Yan TuJifeng FengYi-Long Wu Original Research Article Open access 12 January 2022 Pages: 1 - 13
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study David WaterhouseLaura IadelucaLauren Bartolome Original Research Article Open access 29 December 2021 Pages: 25 - 33
Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features Matt Shirley Correction Open access 24 December 2021 Pages: 93 - 93
MYL-1402O: A Bevacizumab Biosimilar Arnold Lee Adis Biosimilar Brief Open access 15 December 2021 Pages: 85 - 88
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features Matt Shirley Adis Disease Management Open access 14 December 2021 Pages: 69 - 84
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma Veronica MollicaMatteo SantoniFrancesco Massari Original Research Article 11 December 2021 Pages: 61 - 68
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice Lishi LinEgbert F. SmitAlwin D. R. Huitema Original Research Article Open access 11 December 2021 Pages: 53 - 59
Correction to: Durvalumab: A Review in Extensive-Stage SCLC Zaina T. Al-Salama Correction Open access 06 December 2021 Pages: 91 - 91
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies Toshio ShimizuYasutoshi KubokiKyu-pyo Kim Original Research Article Open access 29 November 2021 Pages: 15 - 24
Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry Anas AlawawdehCynthia PiantadosiTimothy Jay Price Original Research Article 25 November 2021 Pages: 35 - 41
Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer Arnold Lee Correction Open access 10 November 2021 Pages: 89 - 89
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy) Massimo AgliettaVanna Chiarion-SileniPaola Queirolo Original Research Article Open access 10 November 2021 Pages: 789 - 799
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy Iris Y. ShengShilpa GuptaAlok A. Khorana Original Research Article 06 November 2021 Pages: 813 - 821
Durvalumab: A Review in Extensive-Stage SCLC Zaina T. Al-Salama Adis Drug Evaluation Open access 03 November 2021 Pages: 857 - 864
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09 Akihito TsujiMasato NakamuraMasashi Fujii Original Research Article 31 October 2021 Pages: 753 - 760
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC Yvette N. Lamb Correction Open access 25 October 2021 Pages: 869 - 869
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration Siwen Hu-LieskovanFadi BraitehMelissa L. Johnson Original Research Article Open access 25 October 2021 Pages: 773 - 787
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study Eliza A. HawkesTycel PhillipsStephen M. Ansell Original Research Article Open access 23 October 2021 Pages: 761 - 771
Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis Neil K. MehtaAndraia R. LiTerry A. Day Systematic Review 22 October 2021 Pages: 743 - 752
